[]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : KAN-101 is an investigational treatment for Celiac Disease (CeD). It encompasses a well-described gluten antigen that is implicated in driving the onset of Celiac Disease.

                          Product Name : KAN-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 05, 2023

                          Lead Product(s) : KAN-101

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : KAN-101 is an investigational treatment for Celiac Disease (CeD). It encompasses a well-described gluten antigen that is implicated in driving the onset of Celiac Disease.

                          Product Name : KAN-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 27, 2022

                          Lead Product(s) : KAN-101

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : KAN-101 is an investigational therapy being evaluated as a treatment for individuals with celiac disease, a serious autoimmune disease triggered by ingestion of gluten, for which there are no approved therapeutic treatments available.

                          Product Name : KAN-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 21, 2022

                          Lead Product(s) : KAN-101

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Anokion and Pfizer have entered into an agreement to leverage Pfizer’s development expertise and capabilities in support of the continued clinical development of KAN-101, Anokion’s lead candidate for the treatment of individuals with celiac disease.

                          Product Name : KAN-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 18, 2022

                          Lead Product(s) : KAN-101

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Pfizer Inc

                          Deal Size : $35.0 million

                          Deal Type : Financing

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Anokion and Pfizer have entered into an agreement to leverage Pfizer’s development expertise and capabilities in support of the continued clinical development of KAN-101, Anokion’s lead candidate for the treatment of individuals with celiac disease.

                          Product Name : KAN-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 18, 2022

                          Lead Product(s) : KAN-101

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Pfizer Inc

                          Deal Size : $35.0 million

                          Deal Type : Financing

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : VectivBio intends to use the net proceeds, together with its existing cash and cash equivalents, available for sale and short-term deposits: to fund clinical development and pre-commercialization activities for its lead product candidate FE203799 (Apragl...

                          Product Name : FE203799

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          June 15, 2022

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : SVB Securities

                          Deal Size : $30.0 million

                          Deal Type : Public Offering

                          blank